Observational Study of the Effectiveness and Safety of Vismodegib (Erivedge) in Patients Treated in Argentina

Trial Profile

Observational Study of the Effectiveness and Safety of Vismodegib (Erivedge) in Patients Treated in Argentina

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2016

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 30 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
    • 30 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
    • 30 Aug 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top